Drug Trial Radar · NCT05624749
Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)
Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
288
Actual
Start
Apr 21, 2023
Primary completion
Apr 12, 2027
Study completion Apr 9, 2029
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Nov 22, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The trial will evaluate efficacy, safety and tolerability of ianalumab compared to placebo, given as monthly subcutaneous (s.c.) injection on top of standard-of-care (SoC) treatment in participants with active systemic lupus erythematosus (SLE).
Conditions
- Systemic Lupus Erythematosus
Interventions
ianalumabDrug
ianalumab s.c. monthly
placeboDrug
placebo s.c. monthly
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants achieving Systemic Lupus Erythematosus Responder Index -4 (SRI-4)Time frame: Week 60
Locations
90 sites in 15 countries. Site status is shown where the registry gives one.
Pinnacle Research Group LLC
Anniston, Alabama
Advanced Medical Research
La Palma, California
University of California LA
Los Angeles, California
Homestead Assoc In Research Inc
Homestead, Florida
IRIS Research and Development
Plantation, Florida
Emory University
Atlanta, Georgia
Willow Rheumatology Wellness
Willowbrook, Illinois
Bluegrass Community Research Inc
Lexington, Kentucky
Accurate Clinical Research
Lake Charles, Louisiana
UMC New Orleans
New Orleans, Louisiana
University Of Maryland
Baltimore, Maryland
Ahmed Arif Medical Research Center
Grand Blanc, Michigan
Washington Univ School Of Medicine
St Louis, Missouri
West Tennessee Research Institute
Jackson, Tennessee
Novel Research LLC
Bellaire, Texas
Novartis Investigative Site
Caba, Argentina
Novartis Investigative Site
Caba, Argentina
Novartis Investigative Site
San Miguel de Tucumán, Argentina
Novartis Investigative Site
La Plata, Buenos Aires, Argentina
Novartis Investigative Site
Quilmes, Buenos Aires, Argentina
Novartis Investigative Site
San Miguel, Buenos Aires, Argentina
Novartis Investigative Site
San Miguel, Tucumán Province, Argentina
Novartis Investigative Site
St Leonards, Australia
Novartis Investigative Site
Maroochydore, Queensland, Australia
Novartis Investigative Site
Concepción, Biobio, Chile
Novartis Investigative Site
Valdivia, Los Ríos Region, Chile
Novartis Investigative Site
Santiago, RM, Chile
Novartis Investigative Site
Santiago, Santiago Metropolitan, Chile
Novartis Investigative Site
Bogotá, Colombia
Novartis Investigative Site
Medellín, Antioquia, Colombia
Novartis Investigative Site
Barranquilla, Atlántico, Colombia
Novartis Investigative Site
Barranquilla, Atlántico, Colombia
Novartis Investigative Site
Chía, Cundinamarca, Colombia
Novartis Investigative Site
Bucaramanga, Santander Department, Colombia
Novartis Investigative Site
Cali, Valle del Cauca Department, Colombia
Novartis Investigative Site
Montpellier, France
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Toulouse, France
Showing 40 of 90 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.